Cefonicid, a parenterally administered semisynthetic
cephalosporin, produces high and sustained serum levels in humans. It is active in vitro against Neisseria gonorrhoeae, including
beta-lactamase-producing strains. Therefore, the efficacy of
cefonicid in treatment of men with uncomplicated gonococcal
urethritis was evaluated in a two-phase study. Initially, 58 men were treated intramuscularly with 1 g of
cefonicid. There were four failures among the 50 patients who could be evaluated. In the second phase (a double-blind study), 57 men received either 1.0 g of
cefonicid or 4.8 x 10(6) units of
procaine penicillin G plus 1.0 g of
probenecid. Among 17 men treated with
penicillin, there were two failures; among the 33
cefonicid-treated patients, there was only one failure. Thus, 78 (94%) of 83 patients receiving
cefonicid were cured. Of the 85 pretreatment and four posttreatment isolates tested, 31 were inhibited by less than 0.0625 microgram of
penicillin/ml and 87 were inhibited by less than 1.0 microgram/ml. Twenty-eight of the 89 isolates were inhibited by less than 0.0625 microgram of
cefonicid/ml and 88, by less than 1.0 microgram of
cefonicid/ml. It is concluded that 1.0 g of
cefonicid given intramuscularly is effective
therapy for uncomplicated gonococcal
urethritis.